Key facts
- This page summarizes Neil Kumar's Form 4 filing for BridgeBio Pharma, Inc. (BBIO).
- 7 reported transactions and 4 derivative rows are listed below.
- Accepted by SEC: 18 May 2023, 16:07.
Neil Kumar - 16 May 2023 Form 4 Insider Report for BridgeBio Pharma, Inc. (BBIO)
- Reporting relationship
- CEO and President, Director
- Issuer ticker
- BBIO
- Reported as of
- 16 May 2023
- Net transaction value
- -$1,436,538
- SEC form
- 4
- Accepted by SEC
- 18 May 2023, 16:07:30 UTC
- Prior SEC filing
- 05 May 2023
- Next SEC filing
- 18 Aug 2023
- Source filing
- View source filing
- Reporting owner signature
- /s/ Brian C. Stephenson, Attorney-in-Fact
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Neil Kumar filed Form 4 for BridgeBio Pharma, Inc. (BBIO) on 18 May 2023.
Change
- Previous filing in this sequence was filed on 05 May 2023.
- Current net transaction value: -$1,436,538.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
BBIO
transaction
Common Stock
Options Exercise
- Transaction value
- Shares
- +102,249
- Change %
- +2.1%
- Price
- Shares after
- 4,915,446
- Date
- 16 May 2023
- Ownership
- Direct
- Footnotes
- F1
BBIO
transaction
Common Stock
Tax liability
- Transaction value
- $714,321
- Shares
- -50,697
- Change %
- -1%
- Price
- $14.09
- Shares after
- 4,864,749
- Date
- 16 May 2023
- Ownership
- Direct
- Footnotes
- F2
BBIO
transaction
Common Stock
Sale
- Transaction value
- $722,218
- Shares
- -51,552
- Change %
- -1.1%
- Price
- $14.01
- Shares after
- 4,813,197
- Date
- 17 May 2023
- Ownership
- Direct
- Footnotes
- F3, F4
BBIO
holding
Common Stock
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 1,012,722
- Date
- 16 May 2023
- Ownership
- See Footnote
- Footnotes
- F5
BBIO
holding
Common Stock
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 995,686
- Date
- 16 May 2023
- Ownership
- See Footnote
- Footnotes
- F6
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
BBIO
transaction
Derivative
Restricted Stock Units
Options Exercise
- Transaction value
- $0
- Shares
- -5,129
- Change %
- -20%
- Price
- $0.000000
- Shares after
- 20,518
- Date
- 16 May 2023
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 5,129
- Exercise price
- Footnotes
- F1, F7
BBIO
transaction
Derivative
Restricted Stock Units
Options Exercise
- Transaction value
- $0
- Shares
- -2,394
- Change %
- -12%
- Price
- $0.000000
- Shares after
- 16,759
- Date
- 16 May 2023
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 2,394
- Exercise price
- Footnotes
- F1, F8
BBIO
transaction
Derivative
Restricted Stock Units
Options Exercise
- Transaction value
- $0
- Shares
- -61,182
- Change %
- -25%
- Price
- $0.000000
- Shares after
- 183,546
- Date
- 16 May 2023
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 61,182
- Exercise price
- Footnotes
- F1, F9
BBIO
transaction
Derivative
Restricted Stock Units
Options Exercise
- Transaction value
- $0
- Shares
- -33,544
- Change %
- -6.2%
- Price
- $0.000000
- Shares after
- 503,160
- Date
- 16 May 2023
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 33,544
- Exercise price
- Footnotes
- F1, F10
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Rule 10b5-1 trading plan
These transactions were reported as open-market trades under a Rule 10b5-1 plan. The plan lets an insider set trading instructions in advance, which can reduce the risk of trading while in possession of material nonpublic information.
Original filing language: transaction made pursuant to a contract, instruction, or written plan intended to satisfy Rule 10b5-1(c).
Explanation of responses 10 footnotes
Footnote F1
Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock.
Footnote F2
Represents number of shares of the Issuer's Common Stock withheld to satisfy the Reporting Person's tax obligation in connection with the vesting of 102,249 shares of Common Stock underlying the Reporting Person's RSUs.
Footnote F3
This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on December 5, 2022.
Footnote F4
Represents the weighted average sale price of the shares sold from $13.82 to $14.22 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions as reported herein.
Footnote F5
The shares are held by Kumar Haldea Revocable Trust, of which the Reporting Person is a co-trustee. The Reporting Person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed to be an admission that such shares are beneficially owned by the Reporting Person for Section 16 or any other purpose.
Footnote F6
The shares are held by Kumar Haldea Family Irrevocable Trust, of which the Reporting Person is a co-trustee. The Reporting Person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed to be an admission that such shares are beneficially owned by the Reporting Person for Section 16 or any other purpose.
Footnote F7
The RSUs vest in sixteen quarterly installments after May 16, 2020, subject to the Reporting Person's continued service with the Issuer or any of its subsidiaries through each vesting date, and have no expiration date.
Footnote F8
The RSUs vest in sixteen quarterly installments after February 16, 2021, subject to the Reporting Person's continued service with the Issuer or any of its subsidiaries through each vesting date, and have no expiration date.
Footnote F9
The RSUs vest with respect to 1/8th of the underlying shares on May 16, 2022. Thereafter, 1/8th of the underlying shares shall vest on a quarterly basis, so that all of the underlying shares shall be vested on February 16, 2024, subject to the Reporting Person's continued service to the Issuer or any of its subsidiaries through each vesting date. The RSUs have no expiration date.
Footnote F10
The RSUs vest with respect to 1/16th of the underlying shares on May 16, 2023. Thereafter, 1/16th of the underlying shares shall vest on a quarterly basis, such that all of the underlying shares shall be vested on February 16, 2027, subject to the Reporting Person's continued service with the Issuer or any of its subsidiaries through each vesting date. The RSUs have no expiration date.